Loading…
avatar for Sean Kassim

Sean Kassim

FDA
Director, Office of Study Integrity and Surveillance, OTS, CDER
Sean serves as the Director of the Office of Study Integrity and Surveillance, CDER/FDA. He oversees the bioavailability/bioequivalence (BA/BE) and GLP inspection programs that inspect and review conduct of regulated pharmaceutical premarket bioanalytical and non-clinical research.